@article{b9f4631f9fbc4e44b3eab525c998307f,
title = "A Case of Full Recovery from Prolonged Cardiac Arrest after Infusion with Paclitaxel and Pembrolizumab",
abstract = "Lung cancer is one of the most common cancers and has the highest risk of mortality in both genders. This devastating cancer is also a significant financial and emotional burden to patients and the healthcare system. Chemotherapy and immunotherapy have become the cornerstone for the treatment of lung cancer. However, treatment may come with severe and sometimes fatal side effects. In this report, we present the case of a 52-year-old Caucasian male who suffered two episodes of prolonged cardiac arrest after the infusion of paclitaxel and pembrolizumab.",
keywords = "Cardiotoxicity, Chemotherapy, Immunotherapy, Lung cancer",
author = "{Sh Ahmed}, Omar and Himil Mahadevia and Rami Manochakian and Yujie Zhao and Manisha Salinas and Andras Khoor and Jordan Legout and Yanyan Lou",
note = "Funding Information: The patient in our case report experienced PEA and heart failure. A TTE done after the cardiac event showed dilated cardiomyopathy with an ejection fraction of 33%, leading to systolic biventricular heart failure with two episodes of cardiac arrest lasting 45 and 8 min, respectively. Of note, this subject{\textquoteright}s ECHO before and after the cardiac arrest was 71% and 63%, respectively, confirming the transient nature of heart failure. This is also supported by the follow-up ECG and ECHO done 4 months after the cardiac arrest incident. In addition to drug toxicities, PTX is known to induce hypersensitivity reaction (HSR), an event mediated through immunological response with symptoms ranging from mild pruritus to anaphylaxis. HSR to PTX is primarily due to type I reactions to cremophor (polysorbate 80), the pharmaceutical vehicle of PTX []. Allergen-specific CD4+ T-cells are known to play a crucial role in type I allergy, and the role of PD-1 signaling in limiting CD4+ T cell responses toward aeroallergens has been previously demonstrated []. This raises the question whether the cardiac arrest observed in the patient could represent a PTX related HSR that was augmented by PD-1 blockade. Funding Information: This study was supported by K12CA090628 (Yanyan Lou). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Publisher Copyright: {\textcopyright} 2022 Case Reports in Ophthalmology",
year = "2022",
month = nov,
day = "28",
doi = "10.1159/000527205",
language = "English (US)",
volume = "15",
pages = "1063--1073",
journal = "Case Reports in Oncology",
issn = "1662-6575",
publisher = "S. Karger AG",
number = "3",
}